Purpose Of Review: There has been a recent renewed interest in the prevalence of antiglycolipid antibodies and their associations with specific clinical phenotypes in Guillain-Barré syndrome. Recent reports have sought to confirm and expand the antibody-phenotype associations of antiganglioside antibodies, antiganglioside-complex antibodies, and antiglycolipid-complex antibodies in the various acute immune-mediated neuropathies. This is a rapidly developing field with technical advances in assay methodology, which have resulted in numerous new putative antibody-phenotype associations.
Recent Findings: Antibodies against single ganglioside species remain the most established serological marker of Guillain-Barré syndrome and its myriad clinical variants. Antibodies against combinations of gangliosides, ganglioside-complex antibodies, detected by the ELISA method have emerged as putative markers of certain clinical features or pathological subtypes, specifically acute motor axonal neuropathy, but do not seem to greatly increase the diagnostic sensitivity of antibody testing as most also react with single ganglioside species. The novel assay method of the combinatorial glycoarray allows high-throughput detection of antibodies recognizing combinations of gangliosides and other glycolipids and early studies suggest it identifies antibody-phenotype associations in addition to significantly increasing the sensitivity of serological testing, including for the acute inflammatory demyelinating polyneuropathy variant.
Summary: Antibodies against single ganglioside species remain diagnostically useful in routine clinical practice. Antibodies against ganglioside complexes, or gangliosides and other glycolipid complexes, are emerging as useful markers of various clinic features and pathological subtypes; however, the precise associations remain to be fully delineated and confirmed. The antibody-complex detection methods are rapidly evolving but in most centres are not yet available in routine clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WCO.0000000000000361 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.
Nat Commun
December 2024
School of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Article Synopsis
- Anti-GD2 antibody therapy offers benefits for neuroblastoma patients, but its effectiveness is limited by the tumor's immunosuppressive environment.
- Research shows that using copper chelation can enhance this therapy by improving immune responses, specifically by boosting the activity of neutrophils that help fight the tumor.
- The study suggests repurposing the approved copper chelator Cuprior as a safe and effective method to improve the outcomes of anti-GD2 therapy in neuroblastoma patients.
[A study on the effects of Anti-GM1 on the differentiation and cytotoxic activity of NK cells in nude mice].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
September 2024
Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Cancer Center, Beijing 100034, China. *Corresponding authors, E-mail:
Article Synopsis
- The study aimed to explore how Anti-ganglioside GM1 antibodies (Anti-GM1) affect the natural killer (NK) cells' ability to kill cancer cells in nude mice by altering their differentiation.
- Researchers used a detailed staining method to identify NK cell characteristics in kidney cancer tissues and immunized mice with GM1 to produce Anti-GM1.
- The results showed that Anti-GM1 significantly reduced NK cell activity, promoted their maturation, and decreased key signaling molecules (IFN-γ and GzmB) involved in their killing function compared to a control group.
Chronic hyperglycemia alters retinal astrocyte microstructure and uptake of cholera toxin B in a murine model of diabetes.
J Neurochem
January 2025
Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Article Synopsis
- Astrocytes are key support cells in the brain that help manage neuron metabolism, and their function may be affected by conditions like diabetes, potentially leading to issues like diabetic retinopathy.
- This study examined changes in the structure of retinal astrocytes in mice with diabetes, finding that chronic high blood sugar can change their shape and function, indicating early disease processes.
- The research highlights the increased activity of astrocytes in response to diabetes, which could influence current treatment approaches for diabetic retinopathy that involve injecting medications into the eye.
Insights into the Pathobiology of GM1 Gangliosidosis from Single-Nucleus Transcriptomic Analysis of CNS Cells in a Mouse Model.
Int J Mol Sci
September 2024
Department of Guangzhou Newborn Screening Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
GM1 gangliosidosis is a lysosomal storage disorder characterized by the accumulation of GM1 ganglioside, leading to severe neurodegeneration and early mortality. The disease primarily affects the central nervous system, causing progressive neurodegeneration, including widespread neuronal loss and gliosis. To gain a deeper understanding of the neuropathology associated with GM1 gangliosidosis, we employed single-nucleus RNA sequencing to analyze brain tissues from both GM1 gangliosidosis model mice and control mice.
View Article and Find Full Text PDFEnhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
Cytotherapy
November 2024
Cell Therapy Center, Beijing Institute of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, and Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China; Center of Neural Injury and Repair, Beijing Institute for Brain Disorders, Beijing, China. Electronic address:
Article Synopsis
- CAR-T cells, which are engineered to target specific antigens, struggle to effectively treat solid tumors like high-risk neuroblastoma due to various challenges, including poor persistence and diverse antigen expressions.
- A new strategy combining CAR-T cells targeting GD2 and GPC2 was developed to enhance treatment effectiveness by using a selective domain that boosts T cell activity when stimulated by a specific antibody.
- Results showed that this combination therapy improved both the immediate and long-term anti-tumor response in laboratory studies, providing hope for better outcomes in treating this aggressive pediatric cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!